A BIFUNCTIONAL TUMOR ACTIVATED IMMUNOMODULATOR (TRACIR) TARGETING PD-L1 AND CD28 IS A POTENT ENHANCER OF T CELL-MEDIATED ANTI-TUMOR ACTIVITY

被引：0

作者：

DiRaimondo, Thomas ^{[1
]}

Budimir, Natalija ^{[1
]}

Ma, Lina ^{[1
]}

Shenhav, Simon ^{[1
]}

Cicchini, Vanessa ^{[1
]}

Navert, Robert ^{[1
]}

Wu, Hua ^{[1
]}

Jocic, Renee ^{[1
]}

Yu, Cuiling ^{[1
]}

Aceveda, Diane ^{[1
]}

Best, Hannah ^{[1
]}

Prentiss, Clara ^{[1
]}

Muskat, Kai ^{[1
]}

Chang, Jason ^{[1
]}

Dastmalchi, Farhad ^{[1
]}

Roup, Fabrece ^{[1
]}

Caffaro, Carolina ^{[1
]}

Aerni, Hans ^{[1
]}

Godfrey, Wayne ^{[1
]}

Winter, Charles ^{[1
]}

Nasoff, Marc ^{[1
]}

Gibson, Neil ^{[1
]}

Campbell, David ^{[1
]}

Salek-Ardakan, Shahram ^{[1
]}

机构：

[1] Janux Therapeut, San Diego, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.1326

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1326

引用

页码：A1377 / A1377

页数：1

共 50 条

[1] A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity
Luan, Yan
Chai, Dafei
Peng, Jianjian
Ma, Shuli
Wang, Min
Ma, Hui
Li, Xiang
Fu, Shilong
Pan, Xiaolong
Wang, Xiaoxiao
Qin, Songbing
Xu, Ting
INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 31 : 248 - 256
[2] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Dahan, Rony
Sega, Emanuela
Engelhardt, John
Selby, Mark
Korman, Alan J.
Ravetch, Jeffrey V.
CANCER CELL, 2015, 28 (03) : 285 - 295
[3] Coupling CD28 co-stimulation to IgTCR-mediated anti-tumor immunity: dynamics of tumor and T cell interactions
Ripley, R
Ma, J
Safar, M
Junghans, RP
Beecham, EJ
CANCER GENE THERAPY, 2001, 8 : S28 - S28
[4] Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity
Breitbart, Eyal
Mendel, Itzhak
Yacov, Niva
MOLECULAR THERAPY, 2017, 25 (05) : 270 - 271
[5] Bifunctional molecular probe targeting tumor PD-L1 enhances anti-tumor efficacy by promoting ferroptosis in lung cancer mouse model
Shao, Chenxu
Yan, Xiaoping
Pang, Shangjie
Nian, Di
Ren, Li
Li, Hui
Sun, Junjie
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 130
[6] FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis (vol 28, pg 285, 2015)
Dahan, Rony
Sega, Emanuela
Engelhardt, John
Selby, Mark
Korman, Alan J.
Ravetch, Jeffrey V.
CANCER CELL, 2015, 28 (04) : 543 - 543
[7] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Ebert, Peter J. R.
Cheung, Jeanne
Yang, Yagai
McNamara, Erin
Hong, Rebecca
Moskalenko, Marina
Gould, Stephen E.
Maecker, Heather
Irving, Bryan A.
Kim, Jeong M.
Belvin, Marcia
Mellman, Ira
IMMUNITY, 2016, 44 (03) : 609 - 621
[8] Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing
Sun, Lin-Lin
Yang, Ri-Yao
Li, Chia-Wei
Chen, Mei-Kuang
Shao, Bin
Hsu, Jung-Mao
Chan, Li-Chuan
Yang, Yi
Hsu, Jennifer L.
Lai, Yun-Ju
Hung, Mien-Chie
AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (07): : 1307 - +
[9] YAP Attenuates CD8 T Cell-Mediated Anti-tumor Response
Lebid, Andriana
Chung, Liam
Pardoll, Drew M.
Pan, Fan
FRONTIERS IN IMMUNOLOGY, 2020, 11
[10] The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 x αPD-L1 bispecific antibody-armed T cells
Cho, Jaewon
Tae, Nara
Song, Yujeong
Kim, Chae-Won
Lee, Seung-Joo
Ahn, Jae-Hee
Lee, Kwang-Ho
Lee, Byung-Hyun
Kim, Byung Soo
Chang, Sun-Young
Kim, Dae Hee
Ko, Hyun-Jeong
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)

← 1 2 3 4 5 →